Diabetic foot ulcers (DFUs) are a common and severe complication of diabetes that affects millions worldwide. DFUs are slow to heal, prone to infections, and often lead to amputations, creating a significant healthcare burden. Existing treatments are costly, inaccessible, or ineffective, and the rising threat of Anti-Microbial Resistance (AMR) further limiting traditional options.
At Gelion Care we focus on developing an innovative solution that will both support faster healing and fight infection while being safe for healthy cells. Our solution is simple to use and suitable for home applications. With that, Gelion Care has the potential to transform DFU care, improving outcomes for millions of patients, reducing hospitalizations, and cutting healthcare costs. It also plays a crucial role in combating AMR by reducing reliance on antibiotics. Through the Biotech Booster program, we aim to bring the product closer to the market.
